English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.

MPS-Authors
/persons/resource/persons203040

Fleer,  E.
Department of Membrane Biophysics, MPI for biophysical chemistry, Max Planck Society;

/persons/resource/persons15029

Eibl,  H. J.
Department of Membrane Biophysics, MPI for biophysical chemistry, Max Planck Society;

External Ressource
No external resources are shared
Fulltext (public)

2404140.pdf
(Publisher version), 567KB

Supplementary Material (public)
There is no public supplementary material available
Citation

Unger, C., Damenz, W., Fleer, E., Kim, D. J., Breiser, A., Hilgard, P., et al. (1989). Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncologica, 28(22), 213-217. doi:10.3109/02841868909111249.


Cite as: http://hdl.handle.net/11858/00-001M-0000-002C-915A-C
Abstract
Hexadecylphosphocholine (He-PC) is a new compound synthesized according to the minimal structural requirements deducted from studies with other ether lipids. In vitro studies on He-PC revealed remarkable antineoplastic activity on HL60, U937, Raji and K562 leukemia cell lines. In addition, He-PC, applied orally, showed a superior effect in the treatment of dimethylbenzanthracene-induced rat mammary carcinomas when compared to intravenously administered cyclophosphamide. After oral application He-PC was well absorbed from the intestine and metabolized in the liver by phospholipases C and D. During a 5-week treatment no hematotoxic effects were detected. In a clinical pilot study on breast cancer patients with widespread skin involvement, topically applied He-PC showed skin tumor regressions without local or systemic side effects.